CR20170107A - Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados - Google Patents

Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados

Info

Publication number
CR20170107A
CR20170107A CR20170107A CR20170107A CR20170107A CR 20170107 A CR20170107 A CR 20170107A CR 20170107 A CR20170107 A CR 20170107A CR 20170107 A CR20170107 A CR 20170107A CR 20170107 A CR20170107 A CR 20170107A
Authority
CR
Costa Rica
Prior art keywords
glucosidase
potentiated
carbon hydrates
rhgaa
powerful acid
Prior art date
Application number
CR20170107A
Other languages
English (en)
Inventor
Hung Do
Russell Gotschall
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CR20170107A publication Critical patent/CR20170107A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Abstract

Composición de alfa glucosidasa humana recombinante (rhGAA) derivada de células CHO que contiene una composición de glicano más optimizada que consiste en una cantidad de rhGAA que contiene N-glicanos que llevan manosa-6-fosfato (M6P) o bis-M6P mayor que las rhGAAs convencionales, junto con una baja cantidad de glicanos de alto contenido en manosa no fosforilados y una baja cantidad de galactosa terminal en oligosacáridos complejos.
CR20170107A 2014-09-30 2015-09-30 Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados CR20170107A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462057842P 2014-09-30 2014-09-30
US201462057847P 2014-09-30 2014-09-30
US201562112463P 2015-02-05 2015-02-05
US201562135345P 2015-03-19 2015-03-19
PCT/US2015/053252 WO2016054231A1 (en) 2014-09-30 2015-09-30 Highly potent acid alpha-glucosidase with enhanced carbohydrates

Publications (1)

Publication Number Publication Date
CR20170107A true CR20170107A (es) 2017-09-01

Family

ID=55631441

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170107A CR20170107A (es) 2014-09-30 2015-09-30 Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados

Country Status (33)

Country Link
US (5) US10208299B2 (es)
EP (2) EP4273241A3 (es)
JP (3) JP6851964B2 (es)
KR (3) KR102306577B1 (es)
CN (2) CN107075468B (es)
AU (2) AU2015325028B2 (es)
BR (1) BR112017005810A2 (es)
CA (2) CA3228032A1 (es)
CL (1) CL2017000722A1 (es)
CO (1) CO2017002776A2 (es)
CR (1) CR20170107A (es)
DK (1) DK3201320T3 (es)
DO (1) DOP2017000079A (es)
EA (1) EA038986B1 (es)
EC (1) ECSP17019103A (es)
FI (2) FI3201320T3 (es)
HR (1) HRP20240041T1 (es)
IL (4) IL289383B2 (es)
LT (1) LT3201320T (es)
MX (2) MX2017003989A (es)
MY (1) MY186336A (es)
NI (1) NI201700039A (es)
PE (1) PE20170906A1 (es)
PH (1) PH12017500455A1 (es)
PL (1) PL3201320T3 (es)
PT (1) PT3201320T (es)
RS (1) RS65066B1 (es)
SG (2) SG10202003753PA (es)
SI (1) SI3201320T1 (es)
SV (1) SV2017005416A (es)
TN (1) TN2017000082A1 (es)
WO (1) WO2016054231A1 (es)
ZA (2) ZA201701945B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3201320T (pt) 2014-09-30 2024-01-12 Amicus Therapeutics Inc Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados
KR20230041833A (ko) * 2015-12-30 2023-03-24 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
LT3957320T (lt) * 2015-12-30 2023-12-11 Amicus Therapeutics, Inc. Patobulinta rūgštinė alfa-gliukozidazė pompe ligos gydymui
TWI823272B (zh) * 2016-03-30 2023-11-21 美商阿米庫斯醫療股份有限公司 用於選擇高m6p重組蛋白之方法
IL301319A (en) 2016-03-30 2023-05-01 Amicus Therapeutics Inc Formulations that include recombinant acid alpha-glucosidase
JP7046003B2 (ja) 2016-03-30 2022-04-01 アミカス セラピューティックス インコーポレイテッド 高ｍ６ｐ組換えタンパク質の選択方法
TW201829770A (zh) * 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
EA202290114A1 (ru) * 2017-03-30 2022-03-29 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
IL270530B1 (en) * 2017-05-15 2024-03-01 Amicus Therapeutics Inc Recombinant human acid alpha-glucosidase
JP2022546587A (ja) 2019-09-06 2022-11-04 アミカス セラピューティックス インコーポレイテッド 生物製剤の捕捉及び精製のための方法
AU2022218792A1 (en) * 2021-02-11 2023-08-24 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
TW202400212A (zh) 2022-05-05 2024-01-01 美商阿米庫斯醫療股份有限公司 用於治療龐貝氏病之方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
ATE258919T1 (de) 1997-11-10 2004-02-15 Searle & Co Verwendung von alkylierten iminozuckern zur behandlung von multipler medikamentenresistenz
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
PT2020438T (pt) 1998-12-07 2018-07-13 Genzyme Corp Tratamento da doença de pompe
ES2311921T3 (es) 1999-02-12 2009-02-16 United Therapeutics Corporation N-(8,8,8-trifluorooctil)1-5,-didesoxi-1,5-imino-d-glucitol para tratar infecciones por el virus de la hepatitis.
EP1196190B1 (en) 1999-07-26 2003-03-19 G.D. SEARLE & CO. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
WO2001097829A2 (en) 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
ES2799882T3 (es) 2000-07-18 2020-12-22 Univ Duke Tratamiento de glucogenosis de tipo II
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
JP2005523882A (ja) 2001-10-16 2005-08-11 アールエックスキネティックス，インコーポレイテッド 高濃度タンパク質製剤および製造の方法
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003086452A2 (en) 2002-04-05 2003-10-23 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy
CA2814767C (en) 2003-01-31 2016-03-15 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
AU2005211775B2 (en) * 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
JP4914224B2 (ja) 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
MX2007014470A (es) 2005-05-17 2008-02-06 Amicus Therapeutics Inc Metodo para el tratamiento de enfermedad de pompe usando derivados de 1-desoxinojirimicina.
CA2669347A1 (en) 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
CN101636200A (zh) * 2006-11-13 2010-01-27 齐斯特治疗公司 用于治疗庞贝氏症的方法
US20100184803A1 (en) 2007-03-09 2010-07-22 Link Medicine Corporation Treatment of Lysosomal Storage Diseases
CA2685332A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US20100317690A1 (en) 2007-11-21 2010-12-16 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
SI2252313T1 (sl) 2008-02-12 2015-08-31 Amicus Therapeutics, Inc. Postopek napovedovanja odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CA2718059A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for pompe disease
MX2010009874A (es) 2008-03-12 2010-11-30 Amicus Therapeutics Inc Tratamiento para la enfermedad de pompe con chaperonas farmacologicas especificas y monitoreo del tratamiento usando marcadores subrogados.
EP3187508A1 (en) * 2008-05-07 2017-07-05 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
US20100119502A1 (en) 2008-11-11 2010-05-13 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
CA3040973A1 (en) * 2008-12-16 2010-07-01 Genzyme Corporation Oligosaccharide-protein conjugates
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
ES2564093T3 (es) 2009-04-09 2016-03-17 Amicus Therapeutics, Inc. Métodos para prevenir y/o tratar trastornos del almacenamiento lisosomal
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
JP5415170B2 (ja) 2009-07-21 2014-02-12 富士フイルム株式会社 複眼撮像装置
KR101824743B1 (ko) 2009-09-29 2018-02-05 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
US20130196410A1 (en) 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
US9347050B2 (en) * 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
MX2013012345A (es) 2011-04-22 2015-05-07 Genzyme Corp Alfa glucosidasa acida modificada con procesamiento acelerado.
ES2660185T3 (es) * 2011-05-27 2018-03-21 Amicus Therapeutics, Inc. Métodos para acoplar péptidos direccionadores a enzimas lisosomales recombinantes para optimizar los tratamientos de las enfermedades por depósito lisosomal
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
JP2014522105A (ja) * 2011-07-22 2014-08-28 インサイト フォトニック ソリューションズ，インコーポレイテッド 波長連続及び規定された時間に対する波長掃引をレーザーから動的及び適応的に生成するシステム及び方法
AU2012359165A1 (en) 2011-12-22 2014-07-10 Centogene Ip Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
JP6236406B2 (ja) 2012-03-07 2017-11-22 アミカス セラピューティックス インコーポレイテッド ポンペ病の処置のための高濃度α−グルコシダーゼ組成物
EP2844279B1 (en) * 2012-05-03 2020-12-09 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
US20150147309A1 (en) 2012-06-06 2015-05-28 Fondazione Telethon Allosteric chaperones and uses thereof
TWI529396B (zh) 2014-07-18 2016-04-11 Mpi Corp Probe card and its transfer circuit board and signal feed structure
PT3201320T (pt) 2014-09-30 2024-01-12 Amicus Therapeutics Inc Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados

Also Published As

Publication number Publication date
RS65066B1 (sr) 2024-02-29
HRP20240041T1 (hr) 2024-03-29
MX2021014565A (es) 2022-01-11
PH12017500455A1 (en) 2017-07-31
AU2022203498A1 (en) 2022-06-09
WO2016054231A1 (en) 2016-04-07
US10208299B2 (en) 2019-02-19
JP2023078118A (ja) 2023-06-06
CO2017002776A2 (es) 2017-08-10
TN2017000082A1 (en) 2018-07-04
ZA201701945B (en) 2019-06-26
EP3201320B1 (en) 2023-10-11
US20220162578A1 (en) 2022-05-26
KR20170063837A (ko) 2017-06-08
IL277529A (en) 2020-11-30
US20170298335A1 (en) 2017-10-19
NZ729507A (en) 2021-10-29
FIC20240010I1 (fi) 2024-04-03
MX2017003989A (es) 2017-07-07
SG10202003753PA (en) 2020-05-28
PT3201320T (pt) 2024-01-12
CN107075468A (zh) 2017-08-18
IL289383A (en) 2022-02-01
IL277529B (en) 2022-02-01
CN114540327A (zh) 2022-05-27
SI3201320T1 (sl) 2024-02-29
FI3201320T3 (fi) 2024-01-08
EP3201320A1 (en) 2017-08-09
JP7225176B2 (ja) 2023-02-20
NI201700039A (es) 2018-01-05
DOP2017000079A (es) 2017-05-31
EA038986B1 (ru) 2021-11-18
KR102455814B1 (ko) 2022-10-18
US11591583B2 (en) 2023-02-28
US20230203465A1 (en) 2023-06-29
IL251152A0 (en) 2017-04-30
CA2961762C (en) 2024-03-05
PE20170906A1 (es) 2017-07-12
EP4273241A2 (en) 2023-11-08
US11753632B2 (en) 2023-09-12
EA201790724A1 (ru) 2017-08-31
KR20210118977A (ko) 2021-10-01
US10961522B2 (en) 2021-03-30
JP6851964B2 (ja) 2021-03-31
ECSP17019103A (es) 2017-06-30
SG11201702114TA (en) 2017-04-27
JP2021011489A (ja) 2021-02-04
IL307587A (en) 2023-12-01
AU2015325028A1 (en) 2017-03-16
CA2961762A1 (en) 2016-04-07
AU2015325028B2 (en) 2022-02-24
CL2017000722A1 (es) 2017-12-15
KR20220146662A (ko) 2022-11-01
LT3201320T (lt) 2024-01-25
SV2017005416A (es) 2017-08-08
EP4273241A3 (en) 2024-01-24
BR112017005810A2 (pt) 2018-02-27
IL289383B1 (en) 2023-11-01
IL251152B (en) 2021-06-30
ZA201901690B (en) 2022-06-29
IL289383B2 (en) 2024-03-01
MY186336A (en) 2021-07-13
JP2017537604A (ja) 2017-12-21
PL3201320T3 (pl) 2024-03-18
DK3201320T3 (da) 2024-01-08
CN107075468B (zh) 2021-12-24
EP3201320A4 (en) 2018-03-14
CA3228032A1 (en) 2016-04-07
US20190276812A1 (en) 2019-09-12
KR102306577B1 (ko) 2021-10-01
US20210261935A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
CR20170107A (es) Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados
BR112017018919A8 (pt) Proteínas de fusão imunomoduladoras e seus usos
MX2022008085A (es) Moleculas peque?as contra cereblon para mejorar la funcion efectora de los linfocitos t.
BR112016015105A2 (pt) Conjugados var2csa-droga
AR094195A1 (es) Enjuagues bucales de haluros de zinc aminoacidos
BR112017013956B8 (pt) Proteínas de fusão de citocinas
BR112014007146A8 (pt) Vedação com fator reduzido de formato para terminação/fibra óptica para cabo blindado
EP3683321A3 (en) Methods relating to circulating tumor cell clusters and the treatment of cancer
BR112017025322A2 (pt) métodos integrados para tratamento de material lignocelulósico
BR112017019072A2 (pt) membrana de troca de íons, sistemas eletroquímicos, e métodos
MY191789A (en) Production of glycolaldehyde by thermolytic fragmentation
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
BR112018070189A2 (pt) método para seleção de proteínas recombinantes ricas em m6p
BR112017013576A2 (pt) produção melhorada de lipídios de núcleo em leveduras oleaginosas
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
BR112017027311A2 (pt) microorganismos de propagação & métodos relacionados & sistemas
EA201990034A1 (ru) Ферментативное гликозилирование стевиолгликозидов и других соединений с глюкозо-1-фосфатом
BR112017002056A2 (pt) porta acústica impermeável em dispositivo auditivo preso à orelha
MX2021006458A (es) Pared celular de levadura enriquecida en proteina de manano-oligosacarido.
EA038931B9 (ru) Композиции и способы получения полипептидов с модифицированным профилем гликозилирования в клетках растений
BR112015013567A8 (pt) extrato de algas que compreende polissacarídeos polianiônicos sulfatados e não sulfatados e suas aplicações.
MY182182A (en) Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars
BR112018015626A2 (pt) sistema fúngico de produção de alto nível de proteínas
CR20160225A (es) Glicoproteínas recombinantes y sus usos
BR112018072551A2 (pt) método de tratamento de câncer urotelial do trato inferior